According to Bloomberg sources, Sanofi is weighing a sale of some of its older anti-inflammatory products, as it attempts to streamline operations and focus on more innovative new therapies.
Sources told Bloomberg that the French drugmaker is reviewing its options for the assets — which include several mature inflammation treatments that could be worth as much as $234 million — reaching out to potential private equity and strategic buyers.
Last December, Sanofi CEO Paul Hudson unveiled a cost-efficiency initiative of $2.2 billion and strategic growth plan with an emphasis on certain key commercial products and pipeline candidates. The CEO began ramping up his efforts to reform the company at its executive level earlier this year, announcing the departure of several executives as part of the restructuring strategy.
This past August, Sanofi agreed to acquire U.S. biotech company Principia Biopharma for $3.4 billion, upping the drugmaker's stake in innovative specialty therapies.
Sanofi declined to comment on Bloomberg's report.